ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ALKS Stock Price » ALKS Stock News

Alkermes Share News

 Alkermes (mm) Stock Price
ALKS Stock Price
 Alkermes (mm) Stock Chart
ALKS Stock Chart
 Alkermes (mm) Stock News
ALKS Stock News
 Alkermes (mm) Company Information
ALKS Company Information
 Alkermes (mm) Stock Trades
ALKS Stock Trades

Eli Lilly Type-1 Diabetes Drug Fails Trial Efficacy Endpoint

DOW JONES NEWSWIRES Eli Lilly & Co. (LLY) and its partner in licensing diabetes-drug candidate teplizumab said the treatment failed to reach the main efficacy goal a late-stage study. As a results, Lilly and MacroGenics Inc. suspended further enrollment and dosing of patients in two other ongoing clinical trials of the treatment effect in type-1 diabetes. Teplizumab, which the companies license from PDL BioPharma Inc. (PDLI), was being tested to treat newly diagnosed type-1 diabetes, the less-common type of the disease. The treatment was meant to slow its progression. Gwen Krivi, a Lilly executive in diabetes product development, called the drug's failure to reach the primary endpoint "obviously disappointing. She said the two companies will be considering all options for teplizumab. Under the licensing arrangement, Lilly agreed to pay PDL BioPharma fees during testing of teplizumab and would pay royalties on sales if the drug is approved. The trial results follow other another disappointment for Lilly on a diabetes drug-candidate earlier this week. The Food and Drug Administration held off on approving the company's long-acting version of diabetes drug Byetta, requesting more testing and data analysis. Eli Lilly is developing the drug with Amylin Pharmaceuticals Inc. and Alkermes Inc. (ALKS). The approval was widely expected. Lilly shares were down 0.2% at $35.95 in after-hours trading, while PDL closed the regular session Wednesday up 2.2% at $5.59 and wasn't active after the close. -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291; joan.solsman@dowjones.com

Stock News for Alkermes (ALKS)
DateTimeHeadline
05/22/201518:32:54Statement of Changes in Beneficial Ownership (4)
05/22/201518:31:15Statement of Changes in Beneficial Ownership (4)
05/22/201518:28:46Statement of Changes in Beneficial Ownership (4)
05/22/201518:02:13Statement of Changes in Beneficial Ownership (4)
05/22/201517:58:51Statement of Changes in Beneficial Ownership (4)
05/22/201517:48:21Statement of Changes in Beneficial Ownership (4)
05/22/201517:43:49Statement of Changes in Beneficial Ownership (4)
05/22/201517:40:11Statement of Changes in Beneficial Ownership (4)
05/21/201517:04:15Statement of Changes in Beneficial Ownership (4)
05/13/201518:06:47Statement of Changes in Beneficial Ownership (4)
05/11/201516:12:00Alkermesâ Corporate Presentation to be Webcast at the UBS Global H...
05/04/201518:06:15Statement of Changes in Beneficial Ownership (4)
05/04/201517:41:39Statement of Changes in Beneficial Ownership (4)
05/01/201503:14:15Alkermes Plc's "Overweight" Rating Reiterated at JPMorgan Chase...
04/30/201508:21:01Quarterly Report (10-q)
04/30/201507:06:35Current Report Filing (8-k)
04/30/201507:00:00Alkermes plc Reports First Quarter 2015 Financial Results
04/23/201517:18:42Statement of Changes in Beneficial Ownership (4)
04/23/201517:13:54Statement of Changes in Beneficial Ownership (4)
04/23/201516:00:00Alkermes to Host Conference Call to Discuss First Quarter 2015...

Alkermes and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad